Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad299 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Norah Terrault. Beteiligte Einrichtung: Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles. Hauptthemen laut MEDLINE: Hepatitis C, Hepacivirus, Hepatitis C Antibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In November 2021, the United States Food and Drug Administration reclassified 2 types of hepatitis C virus (HCV) diagnostic tests (HCV antibody and HCV nucleic acid) from class III to class II, providing a less burdensome pathway to market for diagnostic companies. This down-classification is anticipated to facilitate innovation in HCV diagnostics, particularly for new point-of-care viral detection assays, and ultimately support HCV elimination efforts by increasing the ease of screening as well as test-and-treat models of HCV care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles.
ORCID-Profile: Norah Terrault
Zitieren
APA
Terrault, N. (2024). Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad299
Vancouver
Terrault N. Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad299
BibTeX
@article{Terrault2024,
author = {Terrault, Norah},
title = {Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad299}
}
EUVIMED